COPENHAGEN, June 9, 2022 /PRNewswire/ — MC2 Therapeutics A/S, a commercial-stage pharmaceutical company, has appointed Lars IversenMD, DMSc, Esteemed Chair Professor of Dermatology at Aarhus University Hospital and Aarhus University, its new full-time chief medical officer (CMO) as of October 1stst2022.
Teacher Lars Iversen will be a key member of the MC2 Therapeutics leadership team. He will be responsible for the continued high quality of the company’s strategy, direction and execution of clinical development plans. Duties will also include identifying new first indication or best-in-class projects in autoimmune and inflammatory diseases (I&I) and maintaining and expanding the network of healthcare professionals, patient organizations and medical and scientific advisors from MC2 Therapeutics. in the United States and Europe.
“Lars Iversen brings to the company substantial experience and an extensive international network in the field of dermatology,” said Jesper J Lange, CEO of MC2 Therapeutics. “As part of his research and his participation in numerous clinical trials, Lars has received several awards for his work. His expertise will play a central role in our commitment to redefining the patient treatment experience and addressing the unmet needs of people with chronic autoimmune and inflammatory diseases. ”
Teacher Lars Iversen has been a board member of the International Psoriasis Council (IPC) since 2017. He has carried out a wide range of work and collaborations on national and international committees and has been a guest speaker at several international conferences in Asia, Europe, and United States. Lars Iversen has authored or co-authored 250 articles, reviews or book chapters and patents and has served as a sub-investigator or principal investigator, as well as national coordinator of several clinical trials over the past 20 years. In 2019, he established the National Center for Autoimmune Diseases at Aarhus University Hospital.
“I look forward to joining MC2 Therapeutics. I have followed the company for years and am impressed with how the team has successfully managed all aspects of Wynzora’s development and launch in the US and In addition, the pipeline is exciting, including new first-indication drug candidates based on MC2’s groundbreaking research in urea-derived diseases,” said Professor Lars Iversen. “I have dedicated my entire career to the field of dermatology and autoimmune diseases and by joining MC2, I now have the opportunity to more directly influence and initiate new projects that meet the needs of patients with a equally committed team.”
Lars Iversen assumes the role of CMO after John SelmerMD who decided to devote more time to his family after a long and impressive career. John Selmer will continue to work for MC2 Therapeutics as Executive Medical Advisor and will focus its efforts on identifying and assisting in the early and clinical development of novel therapies with a unique clinical profile in autoimmune and inflammatory diseases.
Biography teacher Lars Iversen
Lars Iversen (Professor, MD, DMSc) is a Full Professor of Dermatology at the University of Aarhus since 2012. He graduated as a doctor from Aarhus University in 1991 and in 2003 he became a specialist in dermato-venerology. In 2019, he established the National Center for Autoimmune Diseases at Aarhus University Hospital.
Work and collaboration of national and international committees:
From 2008 to 2015, he was a member of the Scientific Advisory Board of the European Skin Research Fund of the European Society for Dermatological Research (ESDR); from 2014 to 2017, chair of the topical treatment working group of the International Council of Psoriasis; since 2017 member of the Board of Directors of the International Psoriasis Council (IPC); from 2017-2018 President-elect of the Danish Society of Dermatology (DDS); from 2018 to 2020 President of the Danish Society of Dermatology (DDS); and from 2019-2020 board member of the Nordic Dermatological Association.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a private, commercial-stage pharmaceutical company committed to redefining the treatment experience and addressing the unmet needs of people with chronic autoimmune and inflammatory diseases. MC2 Therapeutics has developed and commercialized a next-generation topical treatment for plaque psoriasis based on its unique formulation and delivery system, PAD Technology™, and is developing a pipeline of novel first-indication therapies such as CKD-ap 3- 5 (uremic pruritus), lichen sclerosis and Sjogren’s dry eye. MC2 Therapeutics also recently launched its biotech-derived biomee™ skin care line for people with dry, itchy and sensitive skin.
For more information about MC2 Therapeutics Group, please visit www.mc2therapeutics.com
SOURCE MC2 Therapeutic